We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Biokangtai

News List

Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time prnasia
November 22, 2021
At 3 a.m. on November 19, the first batch of more than 4 million doses of adenovirus vector COVID-19 vaccines produced by Shenzhen Kangtai Biological Products Co., Ltd. will depart from...
BIOKANGTAI COVID-19 Vaccine Approved for Phase III Clinical Trial in the Philippines prnasia
August 02, 2021
On July 30, Shenzhen Kangtai Biological Products Co., Ltd. (BIOKANGTAI) was approved by the Philippine Food and Drug Administration (PFDA) to launch the phase III clinical trial of its independently developed Inactivated COVID-19 Vaccine (Vero cells) ...
Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia prnasia
June 23, 2021
On June 21, local time, phase III clinical fieldwork of the Inactivated COVID-19 Vaccine (Vero cells) independently developed and manufactured by Shenzhen Kangtai Biological Products Co., Ltd. was officially initiated in Malaysia, and the first batch ...
AstraZeneca signs manufacturing pact with Chinese firm, BioKangtai for COVID-19 vaccine expresspharma
August 07, 2020
As per the deal, AstraZeneca will deliver the first 100 million doses this year and 200 million doses by the end of 2021.